Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
DUBLIN - Goldman Sachs & Co. LLC disclosed Wednesday its trading position in Avadel Pharmaceuticals PLC (NASDAQ:AVPL), revealing it holds a 1.75% long position and a 0.65% short position in the Irish pharmaceutical company.
According to a regulatory filing with the Irish Takeover Panel, Goldman Sachs held 1,709,916 shares in a long position and 635,737 shares in a short position as of October 28, 2025. The disclosure was made under Rule 38.5(b) of the Irish Takeover Panel Act.
The filing shows Goldman Sachs conducted several transactions on October 28, including purchases of 190 shares at $18.5650 per share. The firm also engaged in various securities lending transactions involving tens of thousands of shares.
Goldman Sachs is serving as an advisor to Avadel Pharmaceuticals, according to the disclosure. The filing indicates the investment bank holds derivatives including a swap position expiring in December 2025 and January 2026.
The disclosure was made in compliance with Irish takeover regulations that require principal traders connected to companies involved in potential takeover situations to report their dealings in relevant securities.
The filing was submitted to the Regulatory News Service (RNS) of the London Stock Exchange on October 29, 2025, as required by Irish financial regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.